Related Experiment Videos
Enzyme replacement therapy for Gaucher disease in Australia
J Goldblatt1, J Szer, J M Fletcher
1Department of Paediatrics, University of Western Australia, Genetic Services of WA, King Edward Memorial Hospital, Perth, Western Australia. Jack.Goldblatt@health.wa.gov.au
Internal Medicine Journal
|March 2, 2005
Summary
Enzyme replacement therapy (ERT) significantly improved Gaucher disease patients' blood counts and reduced organ size. This national program showed beneficial responses, reversing hematological complications and visceromegaly.
Area of Science:
- Biochemistry and Genetics
- Lysosomal Storage Disorders
- Pharmacology
Background:
- Gaucher disease is a sphingolipid metabolism disorder caused by beta-Glucocerebrosidase deficiency.
- Severe forms necessitate effective therapeutic interventions.
- Enzyme replacement therapy (ERT) targets the underlying enzymatic defect.
Purpose of the Study:
- To evaluate the effectiveness of a national enzyme replacement therapy (ERT) program for severe Gaucher disease.
- To assess the impact of ERT on hematological parameters and organ volumes.
Main Methods:
- Prospective analysis of patient data collected every 6 months.
- Assessed hemoglobin (Hb) and platelet (plt) concentrations.
- Measured liver and spleen volumes in 48 patients (Type 1 and Type 3B) over 6-114 months.
Main Results:
- Hemoglobin normalized in 85% of patients, with a mean increase of 20 g/L.
- Platelet counts improved significantly, reaching 75% normal levels by study end.
- Mean spleen volume reduced by 56%, and liver volume by 27% in evaluable patients.
Conclusions:
- Enzyme replacement therapy (ERT) demonstrated a range of positive effects in Gaucher disease patients.
- All patients showed improvement in hematological complications and/or reduction in organ enlargement (visceromegaly).
- Further studies will investigate ERT's effects on bone disease, growth, and quality of life.